Skip to content

A Multicenter, Prospective, Open Label, Single-Arm Study of a Novel Pain Management Device, AT-04, in Patients with Acute Low Back Pain

A Multicenter, Prospective, Open Label, Single-Arm Study of a Novel Pain Management Device, AT-04, in Patients with Acute Low Back Pain

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2032190209
Enrollment
30
Registered
2020-02-13
Start date
2020-03-17
Completion date
Unknown
Last updated
2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Low Back Pain acute, low back pain

Interventions

Use AT-04 (magnetic field pain management device) at least once daily for at least 30 minutes at a time. However, the total time of usage per day should not exceed 2 hours. The pads of AT-04 can be ap
Magnetic Field Therapy

Sponsors

Miki Kenji
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Age: Patients aged >= 20 to = 40 mm and time from onset of >= 4 weeks to < 3 months (3) Patients who have not received the treatment for acute low back pain or who have received the treatment for acute low back pain without any change in the treatment regimen (including the prescription, dosage and administration) during the 14 days before formal registration (4) Patients with no changes in the degree of pain during the 14 days before formal registration (5) Patients not requiring hospitalization for treatment (6) Patients for whom written consent can be obtained directly from the patient

Exclusion criteria

Exclusion criteria: (1) Patients who have findings of spinal disease other than low back pain and who also have pain attributable to the disease (2) Patients with a history of surgery for spinal or lumbar disease (3) Patients with psychiatric disease that is known to affect the measurement of pain (4) Patients for whom treatment of underlying diseases clearly causing pain such as trauma and arthritis (rheumatic, osteoarthritis and infectious) should be prioritized (5) Patients who are using life-supporting medical electrical equipment such as a heart-lung machine or a pacemaker (6) Patients using wearable medical electrical equipment such as electrocardiograph (7) Patients with a history of drug abuse (including alcohol) (8) Patients with intractable pain whose VAS value is 40 mm or higher despite simultaneous administration of 3 or more of the following drugs: weak opioids such as tramadol, pregabalin, Cymbalta, or Tryptanol (9) Patients who are participating in clinical studies of other drugs or medical devices (10) Patients requiring hospitalization for treatment (11) Patients with dementia severely interfering with daily life (12) Women who wish to become pregnant or are pregnant or lactating (a pregnancy test should be performed if there is a possibility of pregnancy)

Design outcomes

Primary

MeasureTime frame
It will be verified whether the difference between the VAS score at the time of formal registration and the VAS score on the last day of the treatment period meets the performance goal specified separately.

Secondary

MeasureTime frame
Scores on the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) at baseline (at formal registration) and last day.

Contacts

Public ContactIn Guto

Peace of Mind Co., Ltd.

pm@jomdd.com+81-96-352-9600

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026